Kroon, Paul A. and Iyer, Abishek and Chunduri, Prasad and Chan, Vincent and Brown, Lindsay (2010) The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Current Medicinal Chemistry, 17 (23). pp. 2442-2455. ISSN 0929-8673
|HTML Citation||EndNote||Dublin Core||Reference Manager|
Full text not available from this archive.
Official URL: http://dx.doi.org/10.2174/092986710791556032
Identification Number or DOI: doi: 10.2174/092986710791556032
Red wine contains many compounds that may have therapeutic use, including resveratrol (3,4',5-trihydroxy- trans-stilbene). Since resveratrol could be administered both in the diet and as a therapeutic agent, defining appropriate concentrations requires understanding of the pharmacokinetics. Resveratrol absorption is rapid but plasma concentrations are low as it is rapidly and efficiently converted into relatively hydrophilic phase-2 conjugates, and metabolites, which are then rapidly excreted via the urine and bile. Resveratrol is an effective antioxidant in vivo by increasing NO synthesis and also maintaining the reduced intracellular redox state via the thioredoxin system. Further, activation of sirtuins (one class of lysine deacetylases) may mediate the cardiovascular responses shown by resveratrol. Studies on animal models of hu- man disease suggest that resveratrol has the potential to decrease cardiovascular symptoms in patients with myocardial in- farction, arrhythmias, hypertension, cardiomyopathies, fibrosis, atherosclerosis, thrombosis and diabetes, but, as yet, human clinical trials are rare. Cardioprotection by resveratrol in rodent models may rely on mechanisms producing pharmacological preconditioning in the heart including reducing reactive oxygen species, improving vasorelaxation and angigenesis, preventing inflammation and apoptosis, delaying atherosclerosis as well as decreasing cardiovascular remodel- ling. Interventional studies in humans need to be completed before resveratrol can be considered as a standard therapeutic agent. Therefore, future studies should focus on obtaining the level of evidence required to determine whether resveratrol can be added to the list of evidence-based therapies for cardiovascular diseases that includes renin-angiotensin system inhibitors, adrenoceptor antagonists and calcium entry blockers.
|Item Type:||Article (Commonwealth Reporting Category C)|
|Additional Information:||Author version not held.|
|Uncontrolled Keywords:||resveratrol; sirtuins; preconditioning; cardiovascular remodelling|
|Fields of Research (FOR2008):||11 Medical and Health Sciences > 1102 Cardiovascular Medicine and Haematology > 110299 Cardiovascular Medicine and Haematology not elsewhere classified|
11 Medical and Health Sciences > 1101 Medical Biochemistry and Metabolomics > 110199 Medical Biochemistry and Metabolomics not elsewhere classified
11 Medical and Health Sciences > 1115 Pharmacology and Pharmaceutical Sciences > 111501 Basic Pharmacology
|Socio-Economic Objective (SEO2008):||E Expanding Knowledge > 97 Expanding Knowledge > 970111 Expanding Knowledge in the Medical and Health Sciences|
|Deposited On:||03 Jan 2011 20:28|
|Last Modified:||12 Sep 2011 12:14|
Archive Staff Only: edit this record